Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 7, 2011, Pages 943-955

  DiPersio, John F ^a   Ho, Anthony D ^b   Hanrahan, Jessie ^c   Hsu, Frank J ^c   Fruehauf, Stefan ^d  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GENZYME CORPORATION   (United States)

^d Paracelsus Klinik   (Germany)

Author keywords

Acute myeloid leukemia; Hematologic malignancy; Hematopoietic stem cell transplantation; Multiple myeloma; Non Hodgkin's lymphoma; Plerixafor; Tumor cell mobilization

Indexed keywords

CD38 ANTIGEN; CYTARABINE; IMMUNOGLOBULIN G; NATALIZUMAB; NUCLEOPHOSMIN; PLERIXAFOR; PLERIXAFOR PLUS RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; PROTEIN BCL 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CD34 SELECTION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; COMPLEMENTARITY DETERMINING REGION; DNA SEQUENCE; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; IMMUNOCYTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STEM CELL MOBILIZATION; TUMOR CELL MOBILIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYTOKINES; DNA, NEOPLASM; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; RECURRENCE; RISK; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79958753078     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.10.018     Document Type: Review

References (113)

1. Gazitt Y., Tian E., Barlogie B., et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996, 87:805-811.
2. Billadeau D., Quam L., Thomas W., et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992, 80:1818-1824.
3. Ross A.A., Cooper B.W., Lazarus H.M., et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993, 82:2605-2610.
4. Biswas S., Guix M., Rinehart C., et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007, 117:1305-1313.
5. Anagnostopoulos A., Aleman A., Yang Y., et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant 2004, 33:623-628.
6. Kopp H.G., Yildirim S., Weisel K.C., Kanz L., Vogel W. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. J Cancer Res Clin Oncol 2009, 135:637-642.
7. Brenner M.K., Rill D.R., Holladay M.S., et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993, 342:1134-1137.
8. Deisseroth A.B., Zu Z., Claxton D., et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994, 83:3068-3076.
9. Hamlin P.A., Zelenetz A.D., Kewalramani T., et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003, 102:1989-1996.
10. Vose J., Bierman P., Loberiza F., et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008, 14:36-42.
11. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 8:329-340.
12. Hsieh H.B., Marrinucci D., Bethel K., et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006, 21:1893-1899.
13. Krivacic R.T., Ladanyi A., Curry D.N., et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004, 101:10501-10504.
14. Wu G.Q., Sharp J.G., Wu G., Vose J., Greiner T.C., Chan W.C. The detection of minimal lymphoma by molecular and combined culture-molecular methods. Br J Haematol 1997, 99:873-881.
15. Menendez P., Caballero M., Prosper F., et al. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Transfusion 2002, 42:1159-1172.
16. Barlogie B., Johnston D.A., Smallwood L., et al. Prognostic implications of ploidy and proliferative activity in human solid tumors. Cancer Genet Cytogenet 1982, 6:17-28.
17. Bunn P.A., Krasnow S., Makuch R.W., Schlam M.L., Schechter G.P. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications. Blood 1982, 59:528-535.
18. Barlogie B., Raber M.N., Schumann J., et al. Flow cytometry in clinical cancer research. Cancer Res 1983, 43:3982-3997.
19. Barlogie B., Alexanian R., Pershouse M., Smallwood L., Smith L. Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest 1985, 76:765-769.
20. Barlogie B., Gohde W., Johnston D.A., et al. Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry. Cancer Res 1978, 38:3333-3339.
21. Nowak R., Oelschlägel U., Range U., et al. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy. Bone Marrow Transplant 1999, 23:895-900.
22. Santonocito A.M., Consoli U., Bagnato S., et al. Flow cytometric detection of aneuploid CD38(++) plasma cells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res 2004, 28:469-477.
23. Gruszka A.M., Lavorgna S., Irno Consalvo M., et al. A monoclonal antibody against mutated nucleophosmin1 for the molecular diagnosis of acute myeloid leukemias. Blood 2010 Jun 10, [Epub ahead of print].
24. Ross A.A. Detection and significance of minimal residual disease from solid tumor malignancies in stem cell autografts. Hematopoietic Stem Cell Transplantation 2000, 275-290. Informa Healthcare, New York. 1st ed. A.D. Ho, R. Haas, R.E. Champlin (Eds.).
25. Radich J.P., Mao M., Stepaniants S., et al. Individual-specific variation of gene expression in peripheral blood leukocytes. Genomics 2004, 83:980-988.
26. Haas R., Moos M., Karcher A., et al. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994, 12:1685-1692.
27. Mateo G., Corral M., Almeida J., et al. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma. Haematologica 2003, 88:1013-1021.
28. Cook G.P., Tomlinson I.M., Walter G., et al. A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q. Nat Genet 1994, 7:162-168.
29. Hsu F.J., Levy R. Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. Blood 1995, 86:3072-3082.
30. Lopez-Perez R., Garcia-Sanz R., Gonzalez D., et al. The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia 2000, 14:1493-1499.
31. Zhou P., Zhang Y., Martinez C., Kalakonda N., Nimer S.D., Comenzo R.L. Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood 2003, 102:477-479.
32. Corradini P., Ladetto M., Zallio F., et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004, 22:1460-1468.
33. Bakkus M.H., Bouko Y., Samson D., et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 2004, 126:665-674.
34. Cremer F.W., Kiel K., Wallmeier M., Haas R., Goldschmidt H., Moos M. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol 1998, 26:969-975.
35. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999, 17:208-215.
36. Yunis J.J., Oken M.M., Kaplan M.E., Ensrud K.M., Howe R.R., Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982, 307:1231-1236.
37. Price C.G., Meerabux J., Murtagh S., et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 1991, 9:1527-1532.
38. Zelenetz A.D., Chu G., Galili N., et al. Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood 1991, 78:1552-1560.
39. Buchonnet G., Lenain P., Ruminy P., et al. Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3' BCL2 breakpoints and evidence of a new cluster. Leukemia 2000, 14:1563-1569.
40. Dolken G., Dolken L., Hirt C., Fusch C., Rabkin C.S., Schuler F. Age-dependent prevalence and frequency of circulating t(14;18)-positive cells in the peripheral blood of healthy individuals. J Natl Cancer Inst Monogr 2008, 44-47.
41. Falini B., Mecucci C., Tiacci E., et al. GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
42. Ottone T., Ammatuna E., Lavorgna S., et al. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn 2008, 10:212-216.
43. Schmidt H.H., Strehl S., Thaler D., et al. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications. Leukemia 2004, 18:1115-1121.
44. Meloni G., Diverio D., Vignetti M., et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997, 90:1321-1325.
45. Leung W., Chen A.R., Klann R.C., et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 1998, 22:971-979.
46. Ootsuka S., Asami S., Sasaki T., et al. Useful markers for detecting minimal residual disease in cases of neuroblastoma. Biol Pharm Bull 2008, 31:1071-1074.
47. Lemoli R.M., Cavo M., Fortuna A. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma. J Hematother 1996, 5:339-349.
48. Sastre J., Maestro M.L., Puente J., et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008, 19:935-938.
49. Hiraiwa K., Takeuchi H., Hasegawa H., et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol 2008, 15:3092-3100.
50. Gallagher D.J., Milowsky M.I., Ishill N., et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol 2009, 20:305-308.
51. Brugger W., Bross K.J., Glatt M., Weber F., Mertelsmann R., Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994, 83:636-640.
52. Pecora A.L., Lazarus H.M., Jennis A.A., et al. Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol Blood Marrow Transplant 2002, 8:536-543.
53. Cristofanilli M., Broglio K.R., Guarneri V., et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 2007, 7:471-479.
54. Franklin W.A., Glaspy J., Pflaumer S.M., et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood 1999, 94:340-347.
55. Gazitt Y., Reading C., Hoffman R., et al. Purified CD34+ Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood 1995, 86. 381-189.
56. Desikan K.R., Jagannath S., Siegel D., et al. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma. Leuk Lymphoma 1998, 28:501-508.
57. Kiel K., Cremer F.W., Ehrbrecht E., et al. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow Transplant 1998, 21:1109-1115.
58. Knudsen L.M., Rasmussen T., Nikolaisen K., Johnsen H.E. Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma. Eur J Haematol 2001, 67:289-295.
59. Pelus L.M. Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand. Curr Opin Hematol 2008, 15:285-292.
60. Zohren F., Toutzaris D., Klärner V., Hartung H.P., Kieseier B., Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008, 111:3893-3895.
61. Richman C.M., Weiner R.S., Yankee R.A. Increase in circulating stem cells following chemotherapy in man. Blood 1976, 47:1031-1039.
62. Abrams R.A., Johnston-Early A., Kramer C., Minna J.D., Cohen M.H., Deisseroth A.B. Amplification of circulating granulocyte-monocyte stem cell numbers following chemotherapy in patients with extensive small cell carcinoma of the lung. Cancer Res 1981, 41:35-41.
63. Stiff P.J., Murgo A.J., Wittes R.E., DeRisi M.F., Clarkson B.D. Quantification of the peripheral blood colony forming unit-culture rise following chemotherapy. Could leukocytaphereses replace bone marrow for autologous transplantation?. Transfusion 1983, 23:500-503.
64. Körbling M., Dörken B., Ho A., Pezzutto A., Hunstein W., Fliedner T. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986, 67:529-532.
65. Duhrsen U., Villeval J.L., Boyd J., Kannourakis G., Morstyn G., Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988, 72:2074-2081.
66. Socinski M.A., Cannistra S.A., Elias A., Antman K.H., Schnipper L., Griffin J.D. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988, 1:1194-1198.
67. Haas R., Ho A., Bredthauer U., et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990, 18:94-98.
68. Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009, 43:181-195.
69. Schiller G., Vescio R., Freytes C., et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995, 86:390-397.
70. Desikan K., Barlogie B., Jagannath S., et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998, 16:1547-1553.
71. Ho J., Yang L., Banihashemi B., et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2009, 43:223-228.
72. Demirkazik A., Kessinger A., Armitage J.O., et al. Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation. Bone Marrow Transplant 2001, 28:207-212.
73. Narayanasami U., Kanteti R., Morelli J., et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001, 98:2059-2064.
74. Fruehauf S., Ehninger G., Hubel K., et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010, 45:269-275.
75. DiPersio J.F., Bridger G., Calandra G. Effect of plerixafor (AMD 3100) plus G-CSF on tumor cell mobilization among patients with lymphoma. Biol Blood Marrow Transplant 2009, 15:37.
76. Mielcarek M., Torok-Storb B. Phenotype and engraftment potential of cytokine-mobilized peripheral blood mononuclear cells. Curr Opin Hematol 1997, 4:176-182.
77. Fruehauf S., Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 2003, 122:360-375. [corrected].
78. Juarez J., Dela Pena A., Baraz R., et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 2007, 21:1249-1257.
79. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
80. Liesveld J.L., Bechelli J., Rosell K., et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007, 31:1553-1563.
81. Zeng Z., Shi Y.X., Samudio I.J., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113:6215-6224.
82. Dillmann F., Veldwijk M.R., Laufs S., et al. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to imatinib and nilotinib. Leuk Lymphoma 2009, 50:1676-1686.
83. Gazitt Y., Freytes C.O., Akay C., Badel K., Calandra G. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007, 16:657-666.
84. Tricot G., Cottler-Fox M.H., Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010, 45:63-68.
85. Gertz M.A., Witzig T.E., Pineda A.A., Greipp P.R., Kyle R.A., Litzow M.R. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997, 19:337-342.
86. Blystad A.K., Delabie J., Kvaloy S., et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004, 125:605-612.
87. Bourhis J.H., Bouko Y., Koscielny S., et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007, 92:1083-1090.
88. Brown J.R., Feng Y., Gribben J.G., et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007, 13:1057-1065.
89. Kornacker M., Stumm J., Pott C., et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 2009, 20:722-728.
90. Stewart A.K., Vescio R., Schiller G., et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001, 19:3771-3779.
91. Vogel W., Kopp H.G., Kanz L., Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol 2005, 131:214-218.
92. Vose J.M., Sharp G., Chan W.C., et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002, 20:2344-2352.
93. Williams C.D., Goldstone A.H., Pearce R.M., et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996, 14:2454-2464.
94. Sharp J.G., Kessinger A., Mann S., et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996, 14:214-219.
95. Gorin N.C., Labopin M., Blaise D., et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol 2009, 27:3987-3993. Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation.
96. Gorin N.C., Labopin M., Reiffers J., et al. Higher incidence of relapse for acute myelocytic leukemia patients infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood 2010 May 17, [Epub ahead of print].
97. Ljungman P., Bregni M., Brune M., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010, 45:219-234.
98. Lazzarino M., Arcaini L., Bernasconi P., et al. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002, 116:229-235.
99. Arcaini L., Orlandi E., Alessandrino E.P., et al. A model of in vivo purging with rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant 2004, 34:175-179.
100. Voso M.T., Martin S., Hohaus S., et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 2000, 25:957-964.
101. Naparstek E. The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Curr Hematol Malig Rep 2006, 1:220-229.
102. Vescio R.A., Hong C.H., Cao J., et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994, 84:3283-3290.
103. Szczepek A.J., Bergsagel P.L., Axelsson L., et al. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 1997, 89:1824-1833.
104. Shpall E.J., Jones R.B., Bearman S.I., et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994, 12:28-36.
105. Fruehauf S., Haas R., Zeller W., Hunstein W. CD34 selection for purging in multiple myeloma and analysis of CD34+ B cell precursors. Stem Cells (Dayton, Ohio) 1994, 12:95-102.
106. Hundsdörfer P., Fruehauf S., Haberkorn M., Höft R., Haas R., Zeller W. Comparison of different lymphoma cell purging modalities: a experimental study with K422 lymphoma cells. Acta Haematol 1999, 101:185-192.
107. Gahrton G., Svensson H., Cavo M., et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 113:209-216.
108. Shipitsin M., Campbell L.L., Argani P., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
109. Nervi B., Ramirez P., Rettig M.P., Uy G.L., Holt M.S., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 11:6206-6214.
110. Zeng Z., Shi Y.X., Samudio I.J., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 133:6215-6224.
111. Zeng Z., Samudio I.J., Munsell M., et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006, 5:3113-3121.
112. Burger J., Burkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 2007, 137:288-296.
113. Vose J.M., Bierman P.J., Anderson J.R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992, 80:2142-2148.